Volume 23, Number 4—April 2017
Antiviral Drug–Resistant Influenza B Viruses Carrying H134N Substitution in Neuraminidase, Laos, February 2016
||NA amino acid change§
||Mean IC50 ± SD, nmol/L (fold change)†‡||Date specimen collected
||GISAID accession no.
|B/Laos/0080/2016||H134||1.09 ± 0.16 (1)||14.48 ± 1.76 (1)||0.36 ± 0.05 (1)||1.15 ± 0.02 (1)||14 Jan||EPIISL 222862|
|B/Laos/0406/2016||H134N||148.36 ± 14.40 (129)||37.87 ± 1.96 (4)||31.09 ± 3.70 (74)||62.43 ± 4.66 (42)||9 Feb||EPIISL 230596|
|B/Laos/0525/2016||H134N||176.03 ± 11.14 (158)||37.55 ± 5.60 (4)||30.25 ± 2.90 (72)||60.12 ± 2.38 (41)||15 Feb||EPIISL 230599|
|B/Laos/0654/2016||H134N||151.95 ± 16.30 (138)||35.06 ± 5.08 (4)||31.29 ± 0.24 (75)||61.53 ± 1.03 (42)||25 Feb||EPIISL 230600|
*Viruses were isolated and propagated on MDCK cells. Susceptibility was determined using a fluorescence-based neuraminidase (NA) inhibition assay.
†IC50 values (NA inhibitor concentration needed to reduce NA activity by 50%) represent mean ± SD from 3 independent experiments.
‡Fold change compared with the median IC50 value determined for influenza B-Victoria lineage viruses (n = 430) that were circulating worldwide during the 2015‒16 influenza season. Median IC50 values are 1.11, 9.67, 0.42, and 1.47 nM for zanamivir, oseltamivir, peramivir, and laninamivir, respectively. Bold indicates fold increases that correspond to reduced inhibition (5- to 50-fold) or to highly reduced (>50-fold) inhibition by a NAI, as outlined by the World Health Organization Expert Working Group of the Global Influenza Surveillance and Response System for Surveillance on Antiviral Susceptibility (5).
§Amino acid residue 134 in influenza type B NA corresponds to residue Q136 in N1 and N2 NA amino acid numbering (6).
¶Oseltamivir carboxylate was used in NA inhibition assay.
- Burnham AJ, Baranovich T, Govorkova EA. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res. 2013;100:520–34.
- Budd A, Blanton L, Kniss K, Smith S, Mustaquim D, Davlin SL, et al. Update: influenza activity—United States and worldwide, May 22–September 10, 2016. MMWR Morb Mortal Wkly Rep. 2016;65:1008–14.
- Davlin SL, Blanton L, Kniss K, Mustaquim D, Smith S, Kramer N, et al. Influenza activity—United States, 2015–16 season and composition of the 2016–17 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2016;65:567–75.
- Okomo-Adhiambo M, Mishin VP, Sleeman K, Saguar E, Guevara H, Reisdorf E, et al. Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance. Antiviral Res. 2016;128:28–35.
- World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility – Geneva, November 2011 and June 2012. Wkly Epidemiol Rec. 2012;87:369–74.
- Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol. 1993;67:2972–80.
- Kawai N, Ikematsu H, Iwaki N, Maeda T, Satoh I, Hirotsu N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis. 2006;43:439–44.
- Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006;50:2395–402.
- Sugaya N, Mitamura K, Yamazaki M, Tamura D, Ichikawa M, Kimura K, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis. 2007;44:197–202.
- Sheu TG, Deyde VM, Garten RJ, Klimov AI, Gubareva LV. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Res. 2010;85:354–60.
- Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H, Besselaar T, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res. 2015;117:27–38.
- Little K, Leang SK, Butler J, Baas C, Harrower B, Mosse J, et al. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring. Euro Surveill. 2015;20:30060.
- Centers for Disease Control and Prevention. Human influenza virus real-time RT-PCR detection and characterization panel. 510(k) summary. 2008. http://www.accessdata.fda.gov/cdrh_docs/pdf8/k080570.pdf.
- Zhou B, Donnelly ME, Scholes DT, St George K, Hatta M, Kawaoka Y, et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol. 2009;83:10309–13.
- Ma LC, Guan R, Hamilton K, Aramini JM, Mao L, Wang S, et al. A second RNA-binding site in the NS1 protein of influenza B virus. Structure. 2016;24:1562–72.